Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
2011
Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
2014
Intracellular Delivery System for Antibody–Peptide Drug Conjugates
2015 StandoutNobel
Cancer statistics, 2024
2024 Standout
Engineering precision nanoparticles for drug delivery
2020 Standout
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
2010
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
2012 Standout
A view on drug resistance in cancer
2019 StandoutNature
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
2006
Curcumin, the Golden Spice From Indian Saffron, Is a Chemosensitizer and Radiosensitizer for Tumors and Chemoprotector and Radioprotector for Normal Organs
2010 Standout
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
2013 Standout
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
2017 StandoutNobel
Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
2011
Cancer drug resistance: an evolving paradigm
2013 Standout
Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
2012
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Hepatocellular carcinoma
2021 Standout
BCL-2 family antagonists for cancer therapy
2008
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia
2013
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib
2009
Targeted blocking of miR328 lysosomal degradation with alkalized exosomes sensitizes the chronic leukemia cells to imatinib
2019
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
2007
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
2021
Current approach to the treatment of chronic myeloid leukaemia
2017
Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion
2013
Lung cancer: current therapies and new targeted treatments
2016 Standout
ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: Thyroid effects of tyrosine kinase inhibitors
2014
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
2013 Standout
Implementing Genome-Driven Oncology
2017
Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
2014
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Cardiovascular Complications of Cancer Therapy
2009
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
2013 Standout
BCL-2 family isoforms in apoptosis and cancer
2019 Standout
Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
2012
Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance
2012
Flying under the radar: the new wave of BCR–ABL inhibitors
2007
Cancer-related fatigue—mechanisms, risk factors, and treatments
2014 Standout
Cancer-related inflammation and treatment effectiveness
2014 Standout
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
2010 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Cancer Chemotherapy and Cardiac Arrhythmias: A Review
2015
The cancer genome
2009 StandoutNature
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
2016 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia
2016
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up
2015
Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
2014
Cancer treatment and survivorship statistics, 2016
2016 Standout
Cancer statistics, 2016
2016 Standout
SGX393 inhibits the CML mutant Bcr-Abl T315I and preempts in vitro resistance when combined with nilotinib or dasatinib
2008
Cancer statistics, 2015
2015 Standout
Cancer treatment and survivorship statistics, 2019
2019 Standout
Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
2011 StandoutScience
Cancer Genome Landscapes
2013 StandoutScience
Diagnosing and Managing Advanced Chronic Myeloid Leukemia
2015
Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches
2016 Standout
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Clinical Practice Guideline: Bell's Palsy
2013 Standout
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
2014
Translation of the Philadelphia chromosome into therapy for CML
2008
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
2015
A Medicinal Chemist’s Guide to Molecular Interactions
2010 Standout
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
2012
Treatments for chronic myeloid leukemia: a qualitative systematic review
2012
Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia
2014
Works of Md Ariful Haque being referenced
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
2009
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
2010
A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant and -Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP).
2006
Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP).
2007
ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
2010
Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib
2012
A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP).
2006
Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy.
2011
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
2007